Intracellular Lipopolysaccharide Sensing as a Potential Therapeutic Target for Sepsis

Trends Pharmacol Sci. 2019 Mar;40(3):187-197. doi: 10.1016/j.tips.2019.01.001. Epub 2019 Jan 25.

Abstract

Lipopolysaccharide (LPS) sensing in the cytosol by the noncanonical inflammasome leads to pyroptosis and NLRP3 inflammasome activation. This mechanism may be more critical for sepsis development than recognition of LPS by Toll-like receptor 4. LPS is directly binding to its intracellular receptor caspase-4/5/11, mediated by outer membrane vesicles and guanylate-binding proteins that deliver LPS to the cytosol and mediate access of caspases to LPS. Caspase-11-dependent cleavage of gasdermin D is discussed as a link between LPS-induced activation of caspases and pyroptosis or NLRP3 inflammasome activation. Finally, we highlight recently described inhibitors of cytosolic LPS-triggered noncanonical inflammasome activation that might be considered as potential drugs for the treatment of sepsis.

Keywords: IL-1beta; LPS; caspases; outer membrane vesicles; pyroptosis; sepsis.

Publication types

  • Review

MeSH terms

  • Animals
  • Caspases / metabolism
  • Humans
  • Inflammasomes / metabolism
  • Intracellular Signaling Peptides and Proteins
  • Lipopolysaccharides / metabolism*
  • Molecular Targeted Therapy
  • Neoplasm Proteins / metabolism
  • Phosphate-Binding Proteins
  • Sepsis / drug therapy
  • Sepsis / metabolism*

Substances

  • GSDMD protein, human
  • Inflammasomes
  • Intracellular Signaling Peptides and Proteins
  • Lipopolysaccharides
  • Neoplasm Proteins
  • Phosphate-Binding Proteins
  • Caspases